The global 3D bioprinting market size is expected to reach USD 7.39 Billion in 2030 and register a revenue CAGR of 26.3% during the forecast period. 3D bioprinting market revenue growth is due to increasing global geriatric population, presence of various age-related chronic diseases, and lack of organ donors. There is a huge gap between demand and supply of organ transplants and emerging 3D bioprinting technologies can help to bridge this gap. 3D bioprinting is gaining traction from academic sector as well.
Rising prevalence of chronic diseases and increasing investments in development of advanced technologies are driving market revenue growth. 3D bioprinting is currently used to create simple tissue structures in laboratories but is expected to create complete organs for transplant in the coming years. Bioprinting has emerged as a promising technology for fabricating artificial organs and tissues, which revolutionizes diagnosis and treatment of various medical conditions. 3D bioprinting helps companies develop new and innovative regenerative medicines, drug therapies, tissue engineering and stem cell therapies which are attracting attention from pharmaceutical companies and healthcare professionals. Advancements in technology have made 3D bioprinting applicable in cancer therapeutics, skin tissue development, liver modeling, and bone and cartilage development.
Increasing number of stem cell research projects and financial support from various organizations for development of regenerative medicine are factors fueling revenue growth of the market. 3D bioprinting has been successfully performed with use of stem cell types of different potency and lineages. Increasing use of 3D bioprinting in cosmetic surgeries is expected to drive market revenue growth during the forecast period. In plastic surgery, craniomaxillofacial operations require significant symmetry and functionality, which can be simulated and modeled virtually with advanced image processing and computer software. These surgeries involve children with cleft-craniofacial and maxillofacial birth defects, which require stringent precision in the small pediatric anatomy.
Request a Sample@ https://qyresearchmedical.com/sample/119061
Driver: Advancements in technology
Advancement in Artificial Intelligence (AI) is contributing to market growth as AI gives suggestion of best possible printing parameters required to produce biocompatible tissues which can fit these parameters by analyzing data and identifying patterns throughout bioprinting process. AI can predict outcomes of various application of 3D prints which reduce rate of failure in clinical trials. Artificial intelligence can also help to speed-up printing time, increase resolution and eliminate risk of contamination of cells. Complexities of bioprinting span across entire process chain, such as, pre-processing, processing, and post-processing. Integration of machine learning with 3D bioprinting can help with accounting for factors responsible for such complexities which is not possible with traditional mathematical models. Machine Learning (ML) tends to be more robust in real-world in terms of prediction.
Restraint: Lack of skilled professionals
Shortage of skilled professionals to operate technologically advanced 3D bioprinter is hampering market growth. 3D bioprinting is an emerging technology with continuous changes. This has increased demand for skilled professionals who can operate these systems. Additionally, use of bioprinted organs inside human body violates certain religious beliefs which is hindering growth of the market.
Based on component, the global 3D bioprinting market is segmented into 3D bioprinters, biomaterials and scaffolds. 3D bioprinter segment accounted for significant revenue share in 2020 as demand and application of 3D bioprinting is increasing. An increase in number of clinical trials on 3D bioprinted products is expected to decrease animal testing significantly which is not only ethically beneficial but also cost-effective. Clinical trials for development of new drug requires testing on animals with artificially induced affected tissues. With emergence of 3D bioprinting, drug developers will be able to identify the difficulties associated with human clinical trials of new drugs, by classifying them in a short period.
Material Type Insights:
Based on material type, the global 3D bioprinting market is segmented into living cells, hydrogels, and extracellular matrices. Living cells segment accounted for a significant revenue share in 2020 and is expected to register high revenue growth rate during the forecast period due to increased usage of living cells in regenerative medicine and stem cell research.
Based on technology, the global 3D bioprinting market is segmented into microextrusion bioprinting, inkjet bioprinting, magnetic levitation bioprinting, laser-assisted bioprinting, and other technologies.
Microextrusion bioprinting or extrusion-based bioprinting is the most common method of bioprinting 3D structures. This method is used in several academic institutions for organ and tissue research. The flexibility of the process makes it ideal for production in pharmaceutical industries. Microextrusion bioprinting segment is expected to register significant revenue growth rate during the forecast period.
Inkjet bioprinting segment accounted for a significant revenue share in 2020 as it is a relatively mature technology and can integrate several nozzles to simultaneously print cells, biological materials, and growth factors together. The technology has high efficiency and speed which is beneficial to solve organ printing-related problems such as biological activity decline and longer production time. It is also suitable for manufacturing large parts.
Based on application, the global 3D bioprinting market is segmented into research, drug testing and development, regenerative medicine, food testing and others. Food testing segment accounted for significant revenue share in 2020. The advantage of 3D bioprinting of food include cost reduction by usage of exact amount of ingredients, creating attractive lab-grown meat and replacing slow manual process like cake decoration. It also brings creativity and innovation to food industry. In July 2020, KFC introduced 3D bioprinting technology to make chicken nuggets. KFC is working with a Russian 3D bioprinting firm for lab-produced chicken nuggets.
Based on end-use, the global 3D bioprinting market is segmented into pharmaceutical & biotechnology companies, research organizations, and academic institutes. Research application segment accounted for a significant revenue share in 2020 owing to rapid progress in stem cell research, increasing investment to expedite Research and Development (R&D) activities, and rising demand for regenerative medicine due to high prevalence of chronic diseases.
Pharmaceutical & biotechnology companies are highly dependent on technology to furnish demands of the patients. With development of personalized medicines and bio-drugs using 3D bioprinting technology, pharmaceutical & biotechnology companies segment revenue is expected to witness the fastest growth rate during the forecast period.
Based on regional analysis, 3D bioprinting market in market in North America accounted for largest revenue share in 2020. Rise in integration of Information Technology (IT) in healthcare industry at a rapid rate is driving growth of the market in the region. Governments of North American countries are spending heavily to develop latest technologies and therapies for effective treatment. The high number of ongoing clinical trials is also contributing to market revenue growth.
Europe accounted for a significant revenue share in 2020. Large number of research activities in cosmetic surgery sector and increase in number of 3D bioprinting-related conferences to create awareness about the benefits of bioprinting are some of the key factors stimulating growth of market in Europe.
3D bioprinting market revenue in Asia Pacific is expected to grow at a rapid rate during the forecast period owing to increased research activities, rise in demand for organ transplants and increasing initiatives by market players for expansion of 3D bioprinting. Rising adoption of stem cell research and therapies in various countries in Asia Pacific is also contributing to market growth. Moreover, increasing support from government bodies and presence of less-stringent regulations are propelling growth of the market.
Competitive landscape of the global 3D bioprinting market is consolidated with few key players operating on global and regional levels. Key players are engaged in product development and strategic alliances to expand their respective product portfolio and gain a robust footing in the global market. Major players profiled in the market report include Allevi, Inc., Regenovo Biotechnology Co., Ltd., Nano3D Biosciences, Inc., Poietis, Organovo Inc., Cellink AB, Stratasys Ltd., and Aspect Biosystems Ltd.
Initiatives taken by market players are driving growth of the market, for instance:
In December 2021, BICO, a 3D bioprinting firm, and Nanochon, a regenerative joint replacement start-up announced commercial agreement for development of 3D printed implants. Nanochon will purchase product from BICO for USD 1.5 million to develop its 3D printed regenerative joint implants.
In November 2021, CollPlant announced commercial launch of BioInk Platform with Collink.3D for use in 3D bioprinting of human tissues, scaffolds, and organs. The launch supports usage of 3D bioprinting application to advance drug discovery, new product development and tissue testing and drug screening.
Segments Covered in the Report
This report offers historical data and forecasts revenue growth at a global, regional, and country level, and provides analysis of the market trends in each of the sub-segments from 2022 to 2030. For this study, Reports and Data has segmented the global 3D bioprinting market based on component, material type, technology, application, end-use, and region:
3D Bioprinting Market Report Scope
Segments covered By Component Outlook, Material Type Outlook, Technology Outlook, Application Outlook, End-use Outlook, Regional Outlook
By Component Outlook
By Material Type Outlook
By Technology Outlook
Magnetic Levitation Bioprinting
By Application Outlook
Drug Testing and Development
By End-use Outlook
Pharmaceutical & Biotechnology Companies
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/119061/1500
You can place an order or ask any questions, please feel free to contact firstname.lastname@example.org | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: